Kornimate/medical-research-clean huggingface dataset:
cryptosporidium infection and human colorectal cancer

Conditions: Colonic Neoplasms; Cryptosporidiosis

Summary: it has been reported that cryptosporidium parvum, a species of a protozoan frequently isolated from humans and animals, is able to induce digestive adenocarcinoma in a rodent model. consistently, some epidemiological studies have reported an association with cryptosporidiosis in patients with colorectal adenocarcinoma. however, the correlation between cryptosporidiosis and human digestive cancer remains unclear at this time, and it is not known whether this intracellular parasite, considered an opportunistic agent, is able to induce gastrointestinal malignancies in humans. in order to add new arguments for a probable association between cryptosporidiosis and digestive human cancer, the main aim of this study is to determine prevalence and to identify species of cryptosporidium among a french digestive cancer population.


Eligibility criteria:
inclusion criteria: cases: * age ≥ 18 years old * patients with colonic adenocarcinoma/intraepithelial neoplasia diagnosed prior to chemotherapy or radiotherapy who will undergo scheduled surgery. patients with rectal cancer with indication for neoadjuvant treatment will still be included, but only biopsies used for diagnosis will be used * patient capable of receiving informed information * written informed consent * affiliation to a social security scheme controls: * age ≥ 18 years old * patients with endoscopic indication for benign pathology * patients with indication for colectomy for benign pathology * patients with digestive cancer (stomach, oesophagus, biliary, pancreatic, etc.) of any type other than colorectal cancer before chemotherapy or radiotherapy * patient capable of receiving informed information * written informed consent * affiliation to a social security scheme exclusion criteria: * patients undergoing pre-operative chemotherapy. * patients who have already had chemotherapy for less than one year or other immunosuppressive treatment

Keywords: colon cancer cryptosporidiosis prevalence infection and cancer
serum uric acid levels and onset of cardiovascular diseases: a caliber study

Conditions: Stable Angina; Unstable Angina; Myocardial Infarction; Unheralded Coronary Heart Disease Death; Heart Failure; Cardiac Arrest; Transient Ischaemic Attack; Ischemic Stroke; Subarachnoid Hemorrhage; Intracerebral Hemorrhage; Peripheral Arterial Disease; Abdominal Aortic Aneurysm; Atrial Fibrillation

Summary: serum uric acid level is a commonly measured biomarker. the association between serum uric acid level and the risk of developing cardiovascular diseases has been observed in some studies, while others showed controversial results. estimation of this association may help to predict cardiovascular outcomes and may guide new treatment strategies. the hypothesis is that increased serum uric acid level is associated with a range of cardiovascular diseases.

smaller observational studies suggested that increased serum uric acid level is associated with increased incidence of several cardiovascular diseases. associations with specific initial presentations of cardiovascular diseases have not been studied in large cohort from the general population, but may be of interest for use in risk prediction or to guide therapeutic strategies. the aim of this study is to estimate associations between serum uric acid level and initial presentation of a range of cardiovascular diseases. the study will use data from the caliber dataset of clinically collected electronic health record data from england. patients enter the study when they have a blood urate measurement recorded in the dataset, and they are followed up until they experience one of the cardiovascular endpoints, death or transfer out of the participating primary care practice. this study is part of the caliber (clinical disease research using linked bespoke studies and electronic records) programme funded from the national institute for health research (nihr) and wellcome trust. the central theme of the caliber research is linkage of the inpatient hospital episode statistics (hes) with primary care (clinical practice research datalink) and other resources. the overarching aim of caliber is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. caliber has received both ethics approval (ref 09/h0810/16) and ecc approval (ref ecc 2-06(b)/2009 caliber dataset).

Eligibility criteria:
inclusion criteria: * patients registered with a participating general practice during the study period * age 30 years or older at study entry * no record of previous diagnosis of cardiovascular disease * follow up for at least one year before the index date. exclusion criteria: * patients without a measurement of blood urate level during the study period.

Keywords: serum uric acid cardiovascular disease atherosclerosis
enteric-coated mycophenolate sodium on quality of life in patients with gastrointestinal symptoms related to mycophenolate mofetil therapy after kidney transplantation

Conditions: Renal Transplant

Summary: this open, multi-center randomized controlled study is designed to investigate the quality of life in patients with mycophenolate mofetil (mmf)-induced gastrointestinal (gi) adverse events after converting to enteric-coated mycophenolate sodium (ec-mps).


Eligibility criteria:
inclusion criteria: 1. received kidney transplant 2. receiving immunosuppressive regimen that includes mmf 3. patients with gi side effects on standard mmf doses or patients on reduced dose mmf with existing but tolerated/controlled gi side effects. 4. at least 18 years of age 5. willing to provide written informed consent 6. able to meet all study requirements including completing questionnaires and completing four study visits. exclusion criteria: 1. patients with gi symptoms assumed or known not to be caused by medroxyprogesterone acetate (mpa) therapy (e.g. oral bisphosphonate induced, infectious diarrhea) 2. acute rejection \< 1 week prior to study enrollment 3. woman of child-bearing potential who is planning to become pregnant or is pregnant and/or lactating and who is unwilling to use effective means of contraception 4. presence of psychiatric illness (i.e., schizophrenia, major depression) that, in the opinion of the site investigator, would interfere with study requirements 5. undergoing acute medical intervention or hospitalization 6. any other medical condition that, in the opinion of the site investigator based on recall or chart review, would interfere with completing the study, including, but not limited to, visual problems or cognitive impairment. 7. receiving any investigational drug or have received any investigational drug within 30 days prior to study enrollment. additional protocol-defined inclusion/exclusion criteria may apply.

Keywords: qol gi side effects mpa
postoperative residual curarization in 2018

Conditions: Postoperative Residual Curarization

Summary: the primary objective of this study is to evaluate the incidence of postoperative residual curarization, as defined by a train-of-four \<90%, upon postanaesthesia care unit arrival. anesthetists tend to use train-of-four monitoring in the operating theatre to interpret muscle tone. train-of-four monitoring is a widely used term for the peripheral nerve stimulation used in neuromuscular blockade monitoring. hypothesizing a change in our practice since 2006-2012 (cammu g, anesth analg 2006; 102: 426-9 and cammu g, anaesth intensive care 2012; 40: 999-1006), residual neuromuscular block as well as the use of intraoperative neuromuscular transmission monitoring and reversal of neuromuscular blocking agents will again be prospectively evaluated in 2018. the present study aims to compare these three periods (2006-2012-2018) in terms of management of neuromuscular block in the operating room and to look for a relationship with the incidence of postoperative residual curarization.


Eligibility criteria:
inclusion criteria: * 18 years of age or older; * informed consent signed; * admission for elective surgery; * administration of non-depolarizing neuromuscular blocking agents during surgery; * tracheal intubation exclusion criteria: * evidence of renal, hepatic, metabolic, and/or neuromuscular disorders * ejection fraction \<20% * admission for emergency surgery; or cardiothoracic surgery * reoperation during the same hospital admission

Keywords: muscle relaxation
derma pen as treatment of gingivitis induced by orthodontics

Conditions: Gingivitis; Orthodontic Appliance Complication

Summary: although orthodontic therapy frequently improves tooth alignment and appearance, its problems with oral hygiene can make patients highly susceptible to gingivitis. after orthodontic treatment, gingivitis is a typical problem. new treatments that promote healing and decrease inflammation are needed. ascorbic acid and derma pen used together have recently surfaced as a potentially effective therapy option for patients who seeking for periodontal therapy during and after orthodontic treatments.


Eligibility criteria:
inclusion criteria: 1. patients age: 18-25 years . 2. systemically healthy patients. 3. mild to moderate plaque-induced gingivitis patients during orthodontic therapy exclusion criteria: 1. periodontitis. 2. individuals who smoke or those who have tobacco related habits. 3. partially edentulous individuals. 4. individuals who are diagnosed with drug-induced gingival enlargement. 5. pregnant or lactating women
do cardiac health: advanced new generation ecosystem - phase 2

Conditions: Cardiovascular Diseases; Life Style; Quality of Life

Summary: the do change service is designed for cardiac patients who could benefit from lifestyle change and a better disease management. the study aims to support patients with behavior change by providing them with devices and behavioral intervention in order to facilitate long-term behavior change.

the focus of the do change project is on empowering individuals with high blood pressure, ischemic heart disease or heart failure with tools and services to optimally monitor and manage their real-time health condition and disease. the innovative approach of the do change project also involves the patients' surrounding health ecosystem in the process. the traditional difficulties of therapy adherence in a physician-centred care system are radically abandoned and replaced by a patient-centred approach. the approach advocated by do change project focuses on the needs of the patient by not only providing them with innovative tools that assess the patient's real-time health condition, but also offer a variety of behavioural alternatives. the main hypothesis of the do change project is that patients' disease self-management and lifestyle will improve as compared to self-management of patients who receive the care as usual.

Eligibility criteria:
inclusion criteria: * age 18-75 years * diagnosed with cad, hf or ht * having at least two of the following risk factors: smoking, positive family history, increased cholesterol, diabetes, sedentary lifestyle, psychosocial risk factors. * patients should also have access to the internet and have a smartphone (and sufficient knowledge on using personal computer or smartphone) * sufficient knowledge of the countries' native language. * additional inclusion criteria for hf patients only is to have a previous diagnosis of systolic or diastolic heart failure and experience hf symptoms (e.g. shortness of breath, chest pain, exhaustion). exclusion criteria: * significant cognitive impairments (e.g. dementia) * patients who are on the waiting list for heart transplantation * life expectancy \<1 year * life threatening comorbidities (e.g. cancers), * a history of psychiatric illness other than anxiety/depression * patients who do not have access to internet * patients with insufficient knowledge of the local pilot language (dutch, chinese and catalonian).
radiofrequency-based speckle tracking echocardiography to evaluate diastolic function

Conditions: Heart Failure, Diastolic

Summary: the purpose of this study is to evaluate a novel ultrasound system's ability to assess the relaxing properties of the heart compared to current techniques.


Eligibility criteria:
inclusion criteria: * patients scheduled to undergo a clinically indicated left heart cardiac catheterization will be recruited for the study. exclusion criteria: * suspected acute st elevation myocardial infarction. * acute coronary syndrome with active ongoing chest pain * known or suspected acute aortic dissection * known or suspected cardiac tamponade * known history of unoperated constrictive pericarditis * known or suspected severe aortic stenosis or severe mitral regurgitation * heart rhythm other than sinus rhythm on pre-cath ekg * age \< 18 years old * unable to provide informed consent
erector spina muscle distance from the skin at different thoracal elevations

Conditions: Pain, Postoperative; Pain, Back

Summary: in our study, we aimed to calculate the ideal measurement of the distance of the erector spina muscle to the skin and to find the best ultrasonography image at different thoracic levels (t1-t2, t5-t6, t5-t6, t11-t12) and in other positions (lateral-sitting-pron) to improve the quality of the block in patients who will undergo erector spina plan block. our primary goal is to determine which thoracic level the erector spinae muscle is closer to the skin and whether the usg screen image is better. our secondary goal is to find out in which position the erector spinae muscle is closer to the skin and the usg screen image is better.

1- abstract introduction erector spina plana block can be performed in different positions (sitting-lateral-pron) and at different thoracic levels. in our study, we aimed to calculate the ideal measurement of the distance of the erector spina muscle to the skin and to find the best ultrasonography image at different thoracic levels (t1-t2, t5-t6, t5-t6, t11-t12) and in other positions (lateral-sitting-pron) to improve the quality of the block in patients who will undergo erector spina plan block. material and methods a total of 80 patients (40 females and 40 males, asa i-ii) aged 18-65 years were included in the study. the erector spinae muscle was determined at t1-t2, t5-t6, and t11-t12 levels and in lateral, sitting, and prone positions, respectively, with a high frequency 10-15 millihertz linear probe of ultrasound, the distance from the skin to the midline of the ultrasound screen was measured, and the best ultrasound screen image was recorded. erector spina plan block, distance measurement, different positions, interfascial plan block.

Eligibility criteria:
inclusion criteria: patients aged 18-65 years asa (american society of anaesthesiologists) i-ii who were to undergo cholecystectomy who were to undergo mastectomy who were to undergo inguinal hernia who were to undergo thoracic surgery exclusion criteria: patients in whom peripheral nerve block was contraindicated uncooperative patients disabled patients emergency cases patients with scoliosis pregnant and breastfeeding women patients with trauma incision scars in the measured area asa iii-iv-v group patients

Keywords: erector spinae plane block interfascial plan block.
therapy for reading problems in adults after brain injury

Conditions: Dyslexia, Acquired; Brain Injuries; Cerebrovascular Accident

Summary: adults who sustain brain damage due to stroke, head injury, or traumatic surgery may develop difficulty reading. this study examines the effectiveness of behavior-based programs to improve reading ability in these individuals.

acquired disorders of reading (acquired dyslexia) are common in patients with aphasia subsequent to left hemisphere stroke. even when language functions recover sufficiently to enable the patient to return to work, continuing dyslexia often interferes significantly with job performance. this study will evaluate cognitive therapies for the treatment of acquired dyslexia. each therapy is based upon a cognitive neuropsychological model of reading; the therapies target specific types of reading deficit and stem from the question of re-learning versus re-organization of function. the therapies focus on dyslexic disorders stemming from the following underlying deficits: 1) impaired access to the orthographic word form from the visual modality (pure alexia); 2) impaired orthographic/phonologic connections (phonologic/deep dyslexia); and 3) decreased ability to hold phonologic codes in memory (phonologic text alexia). participants in this study will undergo a comprehensive and detailed battery of reading and reading-related tests to determine the underlying impairment causing the reading deficit. based upon the results of these tests, the patient's dyslexic disorder will be characterized and, if appropriate, the patient will be assigned to one of the treatment programs devised specifically for that type of deficit. treatment programs are evaluated for efficacy by comparing the accuracy and speed of reading pre- and post-treatment.

Eligibility criteria:
inclusion criteria * reading deficit subsequent to stroke, traumatic brain injury, brain surgery, or other brain damage * ability to attend 2-3 sessions per week for several months at georgetown university in washington, dc exclusion criteria * history of developmental dyslexia or learning disabilities * best corrected vision less than 20/40 * less than 10 years of formal education * significant memory or comprehension problems

Keywords: cognitive therapy aphasia therapy alexia acquired dyslexia phonological deficits orthographic deficits brain disorders brain injury stroke
ips differentiated cardiomyocytes vein transplantation for chronic heart failure

Conditions: Chronic Heart Failure

Summary: based on the safety evaluation of primates, the best cell transplantation scheme was integrated. one patient with chf caused by coronary heart disease, one patient with chf caused by dilatation and one patient with chf caused by keshan disease were selected and treated with autologous ips differentiated cardiomyocyte intravenous transplantation. the safety evaluation of human body was completed and combined with subjective and objective indexes respectively. structural and functional indicators were used to evaluate the therapeutic effect of cell transplantation. the results of animal experiments confirmed the safety and effectiveness of intravenous myocardial cell transplantation, and clarified its possible mechanism.


Eligibility criteria:
inclusion criteria: * it accords with the diagnostic standard of chronic heart failure. * the etiological diagnosis accords with the corresponding diagnostic standard. * the age is 30\~80 years old. * cardiac function classification is iii- grade iv. * signed informed consent. exclusion criteria: * those who did not meet the diagnostic criteria and were included in the standard. * patients with severe dyspnea (such as copd with pulmonary encephalopathy, upper gastrointestinal bleeding, etc.) accompanied by obvious hypoxemia and hemodynamic instability. * patients with severe primary diseases, such as liver and kidney diseases, hematological diseases, autoimmune diseases, malignant tumors, progressive diseases or diseases with poor prognosis, such as severe infection, severe water and electrolyte disorders, acid-base imbalance. * various infectious diseases. * participants in other clinical trials in the past two months.
postpartum care timing: a randomized trial

Conditions: Postpartum; Pregnancy Related

Summary: the purpose of this study is to determine if shortening the time to initial postpartum visit from six weeks to two weeks can improve clinic visit attendance and decrease usage of the emergency department.

postpartum care is an integral component to completing the maternal peripartum experience and transitioning the patient to well-women care. the american congress of obstetrics and gynecology has recently highlighted the importance of this "fourth stage" of pregnancy suggesting earlier and more comprehensive visits compared to the standard 6-week postpartum visit. specifically they describe that "all women should ideally have contact with a maternal care provider within the first three weeks postpartum" however this is largely derived from expect opinion and retrospective data. the current rate of postpartum visit attendance is as low as 66%, especially in women with scant prenatal care. in the investigators government-funded clinic, the postpartum clinic attendance in 2017 was 69% and many of the patients have co-morbidities, notably a 25% rate of psychiatric illness. additionally, in this population, the investigators have identified a high rate of emergency department (ed) usage (8.7%) within 30 days of delivery suggesting that perhaps an earlier routine visit is ideal and can prevent the use of the ed. the aim therefore is to evaluate the utility of an early postpartum visit at two weeks in addition to a standard six-week visit with a randomized control trial.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * receives antepartum, intrapartum and postpartum care at ucla * speaks english or spanish * provides informed consent for study participation * vaginal, cesarean delivery or operative vaginal delivery exclusion criteria: * cognitive impairment, psychiatric instability, or language barriers that limit her ability to provide informed consent * plans to received postpartum care at other institution

Keywords: breastfeeding contraception emergency department
a study to evaluate the efficacy and safety of mct-sr in patients with gastritis

Conditions: Acute Gastritis; Chronic Gastritis

Summary: this is a multi-center, randomized, double-blind, active-controlled, non-inferiority, phase 3 study to evaluate the efficacy and safety of mct-sr in patients with gastritis.

to contribute greater treatment compliance and patient convenience, the rebamipide sr formulation has been developed.

Eligibility criteria:
inclusion criteria: * adult males and females aged ≥19 and \<75 years * patients diagnosed with acute or chronic gastritis by gastroscopy with at least 1 erosion confirmed by gastroscopy within 7 days prior to the first dose of the investigational product(ip) exclusion criteria: * patients ineligible for gastroscopy * patients who took other drugs for treating gastritis within 2 weeks prior to the first dose of the ip. * patients who have to continue taking drugs that may induce gastritis * other clinically significant medical or psychiatric findings that the investigator considers inappropriate for the study